Friday, July 10, 2026

pharma · Carcinoma, Renal Cell · Human Immunodeficiency Virus (HIV) Infection

Merck KGaA, Darmstadt

Merck KGaA, Darmstadt is a pharma organization headquartered in Darmstadt, DE. Primary therapeutic focus areas include Carcinoma, Renal Cell, Human Immunodeficiency Virus (HIV) Infection, Systemic Lupus Erythematosus, So

Frankfurter Str. 250, Darmstadt, 64293, DE HQ
7,364 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Frankfurter Str. 250, Darmstadt, 64293, DE
Employees
7,364
Programs
63
Drugs
50
Patents
0
Clinical program

alvimopan

Phase 2 · small molecule · Constipation

alvimopan for Constipation is a Phase 2 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).

← All Merck KGaA, Darmstadt, Germany projects Phase 2 small molecule completed

Internal code 3753-009

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 2
Modality
small_molecule
Indication
Constipation
Status
completed
Trials
1